Adaptimmune Therapeutics (ADAP) is a clinical-stage biopharmaceutical company focused on developing novel T-cell therapies targeting cancer indications.The most advanced candidate in the company’s pipeline is afamitresgene autoleucel (or afami-cel), an engineered T-cell therapy for advanced synovial sarcoma, a malignant tumor that affects the tissue around the joints.Since the past month, shares of Adaptimmunehave soared 83.1% compared with the industry’s 7.0% rise. The upside can be attributed to the compl ...